Log in

NASDAQ:INVAInnoviva Stock Price, Forecast & News

$13.80
-0.19 (-1.36 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.62
Now: $13.80
$14.12
50-Day Range
$13.11
MA: $14.02
$15.26
52-Week Range
$7.58
Now: $13.80
$15.62
Volume638,994 shs
Average Volume754,244 shs
Market Capitalization$1.40 billion
P/E Ratio8.07
Dividend YieldN/A
Beta1.05
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Brisbane, California.
Read More
Innoviva logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.89 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INVA
Previous SymbolNASDAQ:THRX
CUSIP88338T10
Phone650-238-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$261.02 million
Cash Flow$1.72 per share
Book Value$3.38 per share

Profitability

Net Income$157.29 million

Miscellaneous

Employees6
Market Cap$1.40 billion
Next Earnings Date7/22/2020 (Estimated)
OptionableOptionable

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

Innoviva (NASDAQ:INVA) Frequently Asked Questions

How has Innoviva's stock been impacted by COVID-19 (Coronavirus)?

Innoviva's stock was trading at $12.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INVA shares have increased by 14.6% and is now trading at $13.80. View which stocks have been most impacted by Coronavirus.

When is Innoviva's next earnings date?

Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Innoviva.

How were Innoviva's earnings last quarter?

Innoviva Inc (NASDAQ:INVA) issued its earnings results on Wednesday, April, 29th. The biotechnology company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.36 by $0.23. The biotechnology company earned $78.68 million during the quarter. Innoviva had a return on equity of 59.11% and a net margin of 66.50%. View Innoviva's earnings history.

Has Innoviva been receiving favorable news coverage?

News stories about INVA stock have trended negative on Tuesday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Innoviva earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Innoviva.

Are investors shorting Innoviva?

Innoviva saw a increase in short interest in June. As of June 15th, there was short interest totaling 12,650,000 shares, an increase of 7.0% from the May 31st total of 11,820,000 shares. Based on an average daily volume of 830,900 shares, the days-to-cover ratio is currently 15.2 days. Currently, 18.4% of the shares of the company are short sold. View Innoviva's Current Options Chain.

Who are some of Innoviva's key competitors?

What other stocks do shareholders of Innoviva own?

Who are Innoviva's key executives?

Innoviva's management team includes the following people:
  • Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)
  • Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)
  • Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
  • Dr. Kevin Kwok, Head of Talent Acquisition & Strategy

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $13.80.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.40 billion and generates $261.02 million in revenue each year. The biotechnology company earns $157.29 million in net income (profit) each year or $1.43 on an earnings per share basis. Innoviva employs 6 workers across the globe.

What is Innoviva's official website?

The official website for Innoviva is www.inva.com.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.